Form 4: Intuitive Surgical CMO Sells Shares Under 10b5-1 Plan

Intuitive Surgical's EVP & Chief Medical Officer, Myriam Curet, sold a significant portion of her common stock holdings through a pre-arranged 10b5-1 trading plan.

Summary

• Myriam Curet, Executive Vice President and Chief Medical Officer of Intuitive Surgical Inc. (ISRG), reported transactions involving the company's common stock.
• On March 2, 2026, Curet acquired 125 shares of common stock through the exercise of a non-qualified stock option at a price of $208.9 per share.
• Also on March 2, 2026, Curet disposed of 125 shares of common stock at a price of $492.59 per share.
• On March 3, 2026, Curet disposed of an additional 4,728 shares of common stock at a price of $487.18 per share.
• All reported transactions were conducted in accordance with a Rule 10b5-1 trading plan, which is set to expire on July 29, 2026.
• Following these transactions, Curet's indirect beneficial ownership by Trust decreased to 409 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While it represents a significant insider sale, the execution under a pre-arranged 10b5-1 plan suggests a routine financial management decision rather than a signal of changing company fundamentals or executive confidence.

Positives

• The shares acquired via option exercise were at a significantly lower price ($208.9) compared to the sale prices ($492.59 and $487.18), indicating a profitable transaction for the executive.
• The transactions were executed under a Rule 10b5-1 trading plan, which demonstrates pre-planning and helps mitigate concerns about trading on material non-public information.

Negatives

• A significant number of shares (4,853 total, with a net reduction of 4,728 shares) were sold by a key executive, which could be interpreted by some investors as a slight reduction in insider confidence, although it is a common practice for diversification or liquidity.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance.

Industry Context

StockSavvy.ai notes that insider sales executed under Rule 10b5-1 plans are a common practice for executives to manage personal finances, diversify their portfolios, or cover tax obligations. These pre-scheduled plans are designed to allow insiders to sell shares without being accused of trading on material non-public information, making such transactions generally less indicative of management's immediate outlook on the company's prospects compared to unscheduled sales.

Stakeholder Impact

• Shareholders: May observe a reduction in executive ownership, but the 10b5-1 plan context typically mitigates concerns about a lack of confidence.
• Employees: No direct impact indicated by this filing.

Next Steps

• The Rule 10b5-1 trading plan under which these transactions occurred is scheduled to expire on July 29, 2026.

Key Dates

Recommendation

The reported transactions are routine insider sales executed under a pre-arranged 10b5-1 plan. Such planned sales are common for executive financial planning, diversification, or liquidity needs and do not typically signal a change in the company's fundamental outlook or warrant a strong buy or sell recommendation. Investors should consider this a neutral event in the context of their broader investment thesis for Intuitive Surgical.

Keywords

ISRG, Intuitive Surgical, Insider Trading, Form 4, Stock Sale, Executive Compensation, 10b5-1 Plan, Medical Devices, Robotic Surgery